Following discovery of the EML4–ALK fusion protein, first-line treatment of NSCLC patients with ALK+ tumors has entailed the use of targeted ALK inhibitors, with crizotinib, the first approved inhibitor in 2011 (39). This evidence concerns the gene EML4 and non-small cell lung carcinoma.